Article

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials-12-01-2002
Volume

Cross-over Trials in Clinical Research

The reviewer calls the second edition of Stephen Senn?s text ?well structured and easy to read.?

External Link - article-42081.pdf

Articles in this issue
Education and Training Directory
Glossary of Clinical Research Terminology
Subject Recruitment
European Regulatory Agencies
Cross-over Trials in Clinical Research
Directory of Professional Societies and Associations

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
How In-Home and Community Strategies Boost Recruitment and Diversity
August 20th 2025

How In-Home and Community Strategies Boost Recruitment and Diversity

Andy Studna, Senior Editor
ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity
August 20th 2025

ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity

Andy Studna, Senior Editor
Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT
August 20th 2025

Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT

Don Tracy, Associate Editor
ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials
August 20th 2025

ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials

Andy Studna, Senior Editor
Phase II Trial Data Lead to FDA Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
August 20th 2025

Phase II Trial Data Lead to FDA Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Don Tracy, Associate Editor
© iDoPixBox - © iDoPixBox - stock.adobe.com
August 20th 2025

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan for EGFR-Mutated NSCLC

Andy Studna, Senior Editor
© 2025 MJH Life Sciences

All rights reserved.